199
IRUS Total
Downloads

SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses

Title: SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses
Authors: Dejnirattisai, W
Huo, J
Zhou, D
Zahradník, J
Supasa, P
Liu, C
Duyvesteyn, HME
Ginn, HM
Mentzer, AJ
Tuekprakhon, A
Nutalai, R
Wang, B
Dijokaite, A
Khan, S
Avinoam, O
Bahar, M
Skelly, D
Adele, S
Johnson, SA
Amini, A
Ritter, TG
Mason, C
Dold, C
Pan, D
Assadi, S
Bellass, A
Omo-Dare, N
Koeckerling, D
Flaxman, A
Jenkin, D
Aley, PK
Voysey, M
Costa Clemens, SA
Naveca, FG
Nascimento, V
Nascimento, F
Fernandes da Costa, C
Resende, PC
Pauvolid-Correa, A
Siqueira, MM
Baillie, V
Serafin, N
Kwatra, G
Da Silva, K
Madhi, SA
Nunes, MC
Malik, T
Openshaw, PJM
Baillie, JK
Semple, MG
Townsend, AR
Huang, K-YA
Tan, TK
Carroll, MW
Klenerman, P
Barnes, E
Dunachie, SJ
Constantinides, B
Webster, H
Crook, D
Pollard, AJ
Lambe, T
OPTIC Consortium
ISARIC4C Consortium
Paterson, NG
Williams, MA
Hall, DR
Fry, EE
Mongkolsapaya, J
Ren, J
Schreiber, G
Stuart, DI
Screaton, GR
Item Type: Journal Article
Abstract: On 24th November 2021, the sequence of a new SARS-CoV-2 viral isolate Omicron-B.1.1.529 was announced, containing far more mutations in Spike (S) than previously reported variants. Neutralization titers of Omicron by sera from vaccinees and convalescent subjects infected with early pandemic Alpha, Beta, Gamma, or Delta are substantially reduced, or the sera failed to neutralize. Titers against Omicron are boosted by third vaccine doses and are high in both vaccinated individuals and those infected by Delta. Mutations in Omicron knock out or substantially reduce neutralization by most of the large panel of potent monoclonal antibodies and antibodies under commercial development. Omicron S has structural changes from earlier viruses and uses mutations that confer tight binding to ACE2 to unleash evolution driven by immune escape. This leads to a large number of mutations in the ACE2 binding site and rebalances receptor affinity to that of earlier pandemic viruses.
Issue Date: 3-Feb-2022
Date of Acceptance: 29-Dec-2021
URI: http://hdl.handle.net/10044/1/94557
DOI: 10.1016/j.cell.2021.12.046
ISSN: 0092-8674
Publisher: Elseiver
Start Page: 467
End Page: 484.e15
Journal / Book Title: Cell
Volume: 185
Issue: 3
Copyright Statement: © 2022 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)
Sponsor/Funder: National Institute for Health Research
UK Research and Innovation
UK Research and Innovation
National Institute for Health Research
National Institute for Health Research
UKRI MRC COVID-19 Rapid Response Call
Funder's Grant Number: RP-2016-07-012
9815274 MC_PC_19025
1257927
HPRU-2012-10064
NIHR201385
MC_PC19025
Keywords: Omicron
RBD
SARS-CoV-2
Spike
immune evasion
receptor interaction
vaccines
variants
OPTIC Consortium
ISARIC4C Consortium
Omicron
RBD
SARS-CoV-2
Spike
immune evasion
receptor interaction
vaccines
variants
06 Biological Sciences
11 Medical and Health Sciences
Developmental Biology
Publication Status: Published
Conference Place: United States
Online Publication Date: 2022-01-04
Appears in Collections:Department of Metabolism, Digestion and Reproduction
Department of Infectious Diseases
National Heart and Lung Institute
Faculty of Medicine
Imperial College London COVID-19



This item is licensed under a Creative Commons License Creative Commons